Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Zebra 365 who wrote (18509)	2/3/1999 11:35:00 AM
From: VLAD	Read Replies (2) \| Respond to of 23519

FWIW, I was trying to find specific information regarding the expiration of Vivus patents for the transurethral delivery of vasodialators for the treatment of ED. Apparently the patents run longer than what has been posted here in the past. According to the 10k form filed back in March of 1997, most of the patents have 20 years from 1995 or until 2015 until they expire. See under page 8 here: sec.gov There are a lot of interesting bits of information that can be found on that form. For example, on the new plant in Lakewood, Vivus initially signed a lease for a 40,000 sqft building (5 year lease ending 2001 for $16,833.33/month) but later decided to expand its lease space and decided to also lease another adjacent 50,000 sqft building (for an additional $21,041.67/month for a total leasing expense of $37,875/month) and built an addition to join the two buildings.